Stifel raises Elanco Animal Health stock price target to $23 on strong product growth

Stifel raised its price target on Elanco Animal Health (ELAN) to $23.00, maintaining a Buy rating, citing robust performance from its Credelio Quattro product, which achieved $100 million in sales and is projected to significantly boost 2026 revenue. This positive outlook is reinforced by ELAN's Q2 2025 earnings and revenue surpassing expectations, anticipated margin accretion from its innovation pipeline, and its upcoming inclusion in the S&P MidCap 400 index, all contributing to the stock's 73% gain over the past six months.

Analysis

Elanco Animal Health (ELAN) is exhibiting strong fundamental momentum, validated by both recent performance and forward-looking analyst upgrades. Stifel has increased its price target to $23.00, maintaining a 'Buy' rating, driven by the outperformance of its new product pipeline. Specifically, the parasite protection product Credelio Quattro has achieved $100 million in sales within eight months and captured approximately 14% of its target market's dollar share. Stifel projects this product alone will add over 150 basis points to revenue growth in 2026, with the full innovation portfolio contributing 400-500 basis points, suggesting significant upside even with a flat base business. This top-line growth is complemented by a favorable margin outlook, as the new products are margin-accretive and the 'Elanco Ascend' initiative offers further efficiency gains, leading to speculation that consensus EBIT margin estimates may be too conservative. The bullish thesis is further supported by a Q2 2025 earnings beat, with adjusted EPS of $0.26 surpassing a $0.20 forecast, and a positive technical catalyst from the company's upcoming inclusion in the S&P MidCap 400 index. While the stock's 73% gain in six months has brought it to a level described as 'fairly valued', the confluence of product cycle strength, financial outperformance, and index-driven demand presents a robust growth narrative.

Key Decisions for Investors

• Given the multiple catalysts including strong product momentum, positive analyst revisions, and imminent S&P MidCap 400 inclusion, investors could consider maintaining or initiating a bullish position on ELAN.
• It is critical to monitor the market share gains of Credelio Quattro and the sales ramp of the broader innovation pipeline, as these are the primary validation points for Stifel's projection of 400-500 basis points in revenue growth for 2026.
• While fundamentals are strong, investors should weigh the stock's significant 73% appreciation over six months and its 'fairly valued' assessment when considering new entry points or position sizing, balancing the growth story against current valuation.